Evidence map›Paper›PMID 42344898›Full record

Trial reportFrontiers in immunology2026

SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.

Lin Cai, Jing Chen, Liming Wu, Xinsuo Duan, Guoqiang Zhang, Yumei Li, Litao Zhang, Lanying Qin, Tongxiang Zeng, Xiaohua Wang and 50 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06299982 (A Multicenter,Randomized,Phase 3 Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque Psoriasis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06299982 phase3unknown statusnot on this map

A Multicenter,Randomized,Phase 3 Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque Psoriasis

TypeinterventionalSponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Ran2024 to 2025Enrolled750ConditionsPlaque Psoriasis PatientsArms608 Q2W, 608 Q4W
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

60 authors.

Lin CaiPeking University People's Hospital, Beijing, China.
Jing ChenThe Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Liming WuHangzhou First People's Hospital, Hangzhou, Zhejiang, China.
Xinsuo DuanAffiliated Hospital of Chengde Medical University, Chengde, Hebei, China.
Guoqiang ZhangThe First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yumei LiAffiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Litao ZhangAffiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin, China.
Lanying QinCangzhou People's Hospital, Cangzhou, Hebei, China.
Tongxiang ZengJingzhou Central Hospital, Jingzhou, Hubei, China.
Xiaohua WangDermatology Hospital of Southern Medical University, Guangzhou, China.
Jinyan WangNingbo Second Hospital (Huamei Hospital), University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.
Kun HuangThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hong RenThe First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Lunfei LiuThe Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
Yangfeng DingShanghai Dermatology Hospital, Shanghai, China.
Yong CuiChina-Japan Friendship Hospital, Beijing, China.
Yunyun ShanHangzhou Third People's Hospital, Hangzhou, Zhejiang, China.
Jianyun LuThe Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiaohua TaoZhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Rixin ChenThe First People's Hospital of Nanyang, Nanyang, Henan, China.
Yin TuThe First Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China.
Min YanShengli Oilfield Central Hospital, Dongying, Shandong, China.
Xiaohong ZhuWuxi Second People's Hospital, Wuxi, Jiangsu, China.
Na QiaoThe First People's Hospital of Qujing, Qujing, Yunnan, China.
Zudong MengShiyan People's Hospital, Shiyan, Hubei, China.
Yu WangThe Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Fang ChengXingtai People's Hospital, Xingtai, Hebei, China.
Yanxia YuanThe First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Jianjian ZhuThe First People's Hospital of Changde, Changde, Hunan, China.
Xiaoping HuPeking University Shenzhen Hospital, Shenzhen, China.
Shuping GuoThe First Hospital of Shanxi Medical University, Taiyuan, Shaanxi, China.
Xiujuan XiaYantai Yuhuangding Hospital, Yantai, Shandong, China.
Xiaoyong ManThe Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhouwei WuShanghai General Hospital, Shanghai, China.
Xuejun ChenSichuan Provincial People's Hospital, Chengdu, Sichuan, China.
Guanzhi ChenThe Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yingxia HePanjin Liaoyou Gem Flower Hospital, Panjin, Liaoning, China.
Dong LvYancheng First People's Hospital, Yancheng, Jiangsu, China.
Yanyan FengChengdu Second People's Hospital, Chengdu, Sichuan, China.
Danqi DengThe Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Songmei GengThe Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Qing GuoSun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Wenli FengThe Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Xiulan ZhuThe Second People's Hospital of Changzhi, Changzhi, Shanxi, China.
Yongjun LiuThe Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Bingjiang LinThe First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Rushan XiaJiangyin Hospital of Traditional Chinese Medicine, Jiangyin, Jiangsu, China.
Chunshui YuSuining Central Hospital, Suining, Sichuan, China.
Juanli FanYuncheng Central Hospital of Shanxi Province, Yuncheng, Shanxi, China.
Mingkai JiThe Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China.
Tiechi LeiRenmin Hospital of Wuhan University, Wuhan, Hubei, China.
Wenlin YangThe Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Meiping YangJiangxi Provincial People's Hospital, Nanchang, Jiangxi, China.
Ying GaoWuhan Central Hospital, Wuhan, Hubei, China.
Weiquan LiYuebei People's Hospital, Shaoguan, Guangdong, China.
Meiying JiangThe Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Jing LouSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China.
Yanli LiuSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China.
Cheng ZhouPeking University People's Hospital, Beijing, China.
Jianzhong ZhangPeking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SSGJ-608 is an anti-interleukin-17A monoclonal antibody with high specificity and high affinity and has shown promising efficacy in treatment of moderate-to-severe psoriasis in preliminary trials. Objective: This multicenter, randomized, open-label, phase 3 trial aimed to further evaluate SSGJ-608 at different dosing intervals (80mg every two weeks and 160mg every four weeks) in patients with moderate-to-severe plaque psoriasis. Methods: A total of 770 patients with moderate to severe plaque psoriasis were randomly assigned (1:1) to receive subcutaneous injections of 80mg of SSGJ-608 every two weeks (Q2W) after a starting dose of 160mg at week 0(608A group), or 160mg of SSGJ-608 every four weeks (Q4W) (608 B group) for 12 weeks. Efficacy was assessed by PASI75 and sPGA 0 or 1 response rates at week 12 as co-primary endpoints, and proportion of patients who achieved PASI90, PASI100 or sPGA score of 0 at week 12 as secondary endpoints. The safety profile was also evaluated. Results: At week12, the proportions of patients achieving PASI75 (92.7% vs. 95.1%) and sPGA 0/1 (80.3% vs. 79.0%) were comparable between the two SSGJ-608 dose regimens. The PASI90, PASI100 and sPGA 0 response rates were 81.0% vs.82.3%, 49.4% vs. 47.5%, and 49.4% vs.47.3% in the 608A group and the 608B group, respectively. In the subgroup of patients previously treated with anti-IL-17 therapy, SSGJ-608 also achieved high clinical response rates at week12. The most common TEAEs were hypertriglyceridemia, upper respiratory tract infection, hyperuricemia, increased alanine aminotransferase and hypercholesterolemia. Both treatment groups demonstrated a favorable safety profile and no new safety signals were identified. Conclusions: SSGJ-608 was highly effective for treating patients with moderate-to-severe plaque psoriasis at 80mg Q2W and 160mg Q4W in a larger population, especially in patients previously treated with anti-IL-17 therapy, and exhibited a favorable tolerability profile in Chinese patients with moderate-to-severe plaque psoriasis. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT06299982.

Indexed as

Antibodies, MonoclonalPsoriasisAdultAntibodies, Monoclonal, HumanizedFemaleHumansInterleukin-17MaleMiddle AgedSeverity of Illness IndexTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedInterleukin-17clinical trialefficacy and safetyIL-17plaque psoriasisSSGJ-608

Identifiers

PMID42344898
PMCPMC13286926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.